Eric Terrebonne
Overview
Explore the profile of Eric Terrebonne including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
703
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Randrian V, Portales F, Bouche O, Thezenas S, Chibaudel B, Mabro M, et al.
J Neurooncol
. 2025 Jan;
172(1):229-238.
PMID: 39747714
Purpose: Availability data are scarce and primarily retrospective in patients with brain metastasis (BM) from gastrointestinal (GI) cancers. The objective of this cohort was to determine prognostic factors for survival...
2.
Cazeneuve N, Bouche O, Leger J, Borg C, Labbe-Devilliers C, Lucidarme O, et al.
Clin Res Hepatol Gastroenterol
. 2024 May;
48(7):102380.
PMID: 38788975
Background: Visceral fat produces angiogenic factors such as vascular endothelial growth factor that promote tumoral growth. However, its influence on outcome for patients with advanced cancer treated with anti-angiogenic agents...
3.
Aparicio T, Henriques J, Svrcek M, Zaanan A, Manfredi S, Casadei-Gardini A, et al.
Br J Cancer
. 2024 May;
131(1):49-62.
PMID: 38745088
Background: Small bowel adenocarcinoma is a rare disease. The genomic profiling tumours according to clinical characteristics and its impact on the prognosis remains unclear. Methods: A pooled analysis of clinical...
4.
Zaanan A, Henriques J, Turpin A, Manfredi S, Coriat R, Terrebonne E, et al.
JNCI Cancer Spectr
. 2023 Sep;
7(5).
PMID: 37774004
Background: Small bowel adenocarcinoma is a rare cancer, and the role of adjuvant chemotherapy for localized disease is still debated. Methods: This retrospective multicenter study included all consecutive patients who...
5.
Hautefeuille V, Walter T, Do Cao C, Coriat R, Dominguez S, Mineur L, et al.
Eur J Endocrinol
. 2023 Aug;
189(2):281-289.
PMID: 37542470
Importance: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) can affect patient health-related quality of life (HRQoL). Appropriate information may improve their adherence to treatment and quality of life. Objective: To evaluate the change...
6.
Aparicio T, Bouche O, Etienne P, Barbier E, Mineur L, Desgrippes R, et al.
Dig Liver Dis
. 2022 Sep;
55(4):541-548.
PMID: 36115817
Background: Colon adenocarcinoma mainly occurs in older patients. Oxaliplatin-based adjuvant chemotherapy improved disease-free survival after stage III colon cancer resection, but this improvement was not demonstrated in older patients. Methods:...
7.
Derangere V, Lecuelle J, Lepage C, Aoulad-Ben Salem O, Allatessem B, Ilie A, et al.
Eur J Cancer
. 2022 Jul;
172:221-230.
PMID: 35785606
Aim: Stratification of colon cancer (CC) of patients with stage II and III for risk of relapse is still needed especially to drive adjuvant therapy administration. Our study evaluates the...
8.
Phelip J, Desrame J, Edeline J, Barbier E, Terrebonne E, Michel P, et al.
J Clin Oncol
. 2021 Oct;
40(3):262-271.
PMID: 34662180
Purpose: Whether triplet chemotherapy is superior to doublet chemotherapy in advanced biliary tract cancer (BTC) is unknown. Methods: In this open-label, randomized phase II-III study, patients with locally advanced or...
9.
Mazard T, Cayrefourcq L, Perriard F, Senellart H, Linot B, De La Fouchardiere C, et al.
Cancers (Basel)
. 2021 Jul;
13(12).
PMID: 34199250
Background: Circulating tumor cells (CTCs) allow the real-time monitoring of tumor course and treatment response. This prospective multicenter study evaluates and compares the early predictive value of CTC enumeration with...
10.
Terlizzi M, Buscail E, Boussari O, Adgie S, Leduc N, Terrebonne E, et al.
Acta Oncol
. 2021 Jul;
60(9):1114-1121.
PMID: 34197269
Background: Neoadjuvant treatment (NAT) is debated for borderline resectable pancreatic cancer (BRPC). This retrospective study assessed the impact of NAT on R0 rate and survival for BRPC patients in comparison...